Enhanced Pharmaceuticals Helios

​The term “HELIOS” is associated with several clinical trials and studies in the pharmaceutical industry, particularly focusing on treatments for various diseases. Here are some notable examples:

1. Amylyx Pharmaceuticals’ HELIOS Trial: Amylyx Pharmaceuticals conducted the HELIOS clinical trial to evaluate AMX0035 in individuals with Wolfram syndrome, a rare genetic disorder. The Phase 2 study demonstrated improvements in pancreatic function and glycemic control among participants.
2. Alnylam Pharmaceuticals’ HELIOS-B Study: Alnylam Pharmaceuticals conducted the HELIOS-B Phase 3 study to assess vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study met all primary and secondary endpoints, showing significant reductions in all-cause mortality and recurrent cardiovascular events.
3. HELIOS Trial for Non-Proliferative Diabetic Retinopathy (NPDR): A Phase I study, known as the HELIOS trial, evaluated the investigational intravitreal AXPAXLI implant (OTX-TKI) for treating NPDR. The one-year results indicated stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS), with the treatment generally well-tolerated.

These studies highlight the diverse applications of the “HELIOS” designation in clinical research, spanning neurological, cardiovascular, and ophthalmic conditions.